Synthetic organic

EGFR Inhibitor is a cell permeable compound that is a highly selective inhibitor of EGFR (epidermal growth factor receptor). Inhibition of EGFR has been shown to induce apoptosis. Mechanistic studies have shown that EGFR inhibition takes place via

EGFR inhibitor 57.

EGFR inhibitor 57.

EGFR/ErbB-2 Inhibitor is a cell-permeable 4-anilino quinazoline compound that acts a potent, reversible, and ATP-competitive inhibitors of EGFR and c-erbB2 (IC|50|= 20 nM &amp: 79 nM, respectively), members of the type I growth factor receptor

EGFR/ErbB-2 Inhibitor is a cell-permeable 4-anilino quinazoline compound that acts a potent, reversible, and ATP-competitive inhibitors of EGFR and c-erbB2 (IC|50|= 20 nM &amp: 79 nM, respectively), members of the type I growth factor receptor

EGFR/ErbB-2 Inhibitor is a cell-permeable 4-anilino quinazoline compound that acts a potent, reversible, and ATP-competitive inhibitors of EGFR and c-erbB2 (IC|50|= 20 nM &amp: 79 nM, respectively), members of the type I growth factor receptor

EGFR/ErbB-2 Inhibitor is a cell-permeable 4-anilino quinazoline compound that acts a potent, reversible, and ATP-competitive inhibitors of EGFR and c-erbB2 (IC|50|= 20 nM &amp: 79 nM, respectively), members of the type I growth factor receptor

EGFR/ErbB-2 Inhibitor is a cell-permeable 4-anilino quinazoline compound that acts a potent, reversible, and ATP-competitive inhibitors of EGFR and c-erbB2 (IC|50|= 20 nM &amp: 79 nM, respectively), members of the type I growth factor receptor

EGFR/ErbB-2 Inhibitor is a cell-permeable 4-anilino quinazoline compound that acts a potent, reversible, and ATP-competitive inhibitors of EGFR and c-erbB2 (IC|50|= 20 nM &amp: 79 nM, respectively), members of the type I growth factor receptor

EGIS-11150.

EGIS-11150.

EGIS-7625.